Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 10, 2007

Transgenomic Inks Analysis Agreement with OSI

  • Transgenomic signed a contract with OSI Pharmaceuticals to complete an analysis of specific cancer pathway genes. According to the company, it has developed a high-throughput, high-sensitivity methodology for characterizing genetic variants implicated in malignant neoplasia. Transgenomic can detect pathogenic genetic mutations through use of high-throughput genome scanning with endonucleases, forward and reverse Sanger sequencing, and variant annotation.

    "The contract with OSI Pharmaceuticals enables Transgenomic to utilize its expertise in genetic variant detection to assist OSI Pharmaceuticals in its development efforts. This contract follows genetic analysis work done with other pharmaceutical companies. It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients," states Transgenomic's president and CEO, Craig Tuttle. 

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.